Abstract

Background Plasmodium falciparum infected red blood cells (iRBC) express variant surface antigens (VSA) of which VAR2CSA is involved in placental sequestration and causes pregnancy-associated malaria (PAM). Primigravidae are most susceptible to PAM whereas antibodies associated with protection are often present at higher levels in multigravid women. However, HIV co-infection with malaria has been shown to alter this parity-dependent acquisition of immunity, with more severe symptoms as well as more malaria episodes in HIV positive women versus HIV negative women of a similar parity.MethodsUsing VAR2CSA DBL-domains expressed on the surface of CHO-745 cells we quantified levels of DBL-domain specific IgG in sera from pregnant Malawian women by flow cytometry. Dissociations constants of DBL5ε specific antibodies were determined using a surface plasmon resonance technique, as an indication of antibody affinities.ResultsVAR2CSA DBL5ε was recognized in a gender and parity-dependent manner with anti-DBL5ε IgG correlating significantly with IgG levels to VSA-PAM on the iRBC surface. HIV positive women had lower levels of anti-DBL5ε IgG than HIV negative women of similar parity. In primigravidae, antibodies in HIV positive women also showed significantly lower affinity to VAR2CSA DBL5ε.ConclusionsPregnant women from a malaria-endemic area had increased levels of anti-DBL5ε IgG by parity, indicating this domain of VAR2CSA to be a promising vaccine candidate against PAM. However, it is important to consider co-infection with HIV, as this seems to change the properties of antibody response against malaria. Understanding the characteristics of antibody response against VAR2CSA is undoubtedly imperative in order to design a functional and efficient vaccine against PAM.

Highlights

  • Pregnancy-associated malaria (PAM) has a major impact on the mother and child [1] and is often associated with the sequestration of Plasmodium falciparum infected red blood cells in the placenta [2,3]

  • Despite previously acquired immunity to non-VAR2CSA expressing P. falciparum malaria, pregnant women are highly susceptible to pregnancy-associated malaria (PAM) [8], leading to maternal anemia, low birth weight, miscarriage and stillbirths [9,10,11]

  • Blantyre, Malawi in late third trimester of pregnancy were enrolled into a study of interactions between HIV and malaria in pregnancy, as described elsewhere [26,31]

Read more

Summary

Introduction

Pregnancy-associated malaria (PAM) has a major impact on the mother and child [1] and is often associated with the sequestration of Plasmodium falciparum infected red blood cells (iRBC) in the placenta [2,3]. Despite previously acquired immunity to non-VAR2CSA expressing P. falciparum malaria, pregnant women are highly susceptible to PAM [8], leading to maternal anemia, low birth weight, miscarriage and stillbirths [9,10,11]. It has been shown that HIV positive women receiving intermittent preventive treatment in pregnancy (IPTp) need additional doses of drugs in order to be protected [28,29,30], further reflecting the need for increased knowledge of antibody dynamics. Plasmodium falciparum infected red blood cells (iRBC) express variant surface antigens (VSA) of which VAR2CSA is involved in placental sequestration and causes pregnancy-associated malaria (PAM). HIV co-infection with malaria has been shown to alter this parity-dependent acquisition of immunity, with more severe symptoms as well as more malaria episodes in HIV positive women versus HIV negative women of a similar parity

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call